Chronetyx® LABORATORIES

Timely, accurate and actionable molecular diagnostics results

Cyx Solid Tumor 505

Cyx Solid Tumor 505 enables rapid and actionable genomic insights for all patients with advanced cancer. FDA-cleared and CE-IVD-marked comprehensive tumor profiling affords every patient access to personalized treatment options.

Product features

- **Trustworthy:** FDA-cleared detection chemistry and CE-IVD-marked with overall clinical pass rate of 92.9%
- **Fast:** Results generated in less than a week via streamlined automation workflow and automated bioinformatics
- **Actionable:** 505 solid tumor-related genes, including all FDA-approved and professional guideline-supported biomarkers, with easy-to-interpret results
- **Automated:** On-site automation improves efficiency, consistency, and reduces human errors

Detection chemistry development & validation

- **Pan solid tumor:** 35 solid tumor types across 9 organ systems
- **Robust:** >7,300 analytical samples tested
- **Rigorous:** 15,000 hours of sequencing time
- **Accurate:** 13 orthogonal methods used for comparison, including PCR, IHC, FISH, RNA and DNA-based NGS approaches

Cyx Solid Tumor 505 Workflow



Chronetyx® LABORATORIES 3171 Players Club Parkway • Memphis, TN 38125 | 800-454-2137 | info@chronetyx.com

Fast, actionable results | **Pathology reports in as little as a week**

Assay Specifications

Sample requirements	FFPE Tissue, Slides, or Blocks
Tumor purity minimum	20%
Regions analyzed	Coding regions of 505 genes; non-coding regions for translocations
Mutation Identification	MSI, TMB, Translocations, Indels, SNVs, & Amplifications
Read length	2.23 Mb total
Average total coverage	2,300x

Sample Pathology Report



Chronetyx LABORATORIES

CYX Solid Tumor 505

Date: 09/25/2024
Order ID: ETCR-KEU-201:
BM80908_2_R1:240920090005

Patient	Specimen	Physician Information
Name: Jane Smith DOB: Gender: Female MRN: ETCRKEU201:BM80908_2_R1:240920090005 Diagnosis: Colorectal Carcinoma	Type: Collected: Received: Specimen ID:	Institution: ABC USA Referring Physician: John Smith, M.D Pathologist: John Doe, M.D.

RESULT SUMMARY

Significant Genomic Variants Detected

Positive Genomic Finding	Tier (AMP/ASCO/CAP)	Actionability
APC E1494fs	2C	None Identified
KRAS G12C	1A	Approved Therapies Therapy Resistance 6 Clinical Trials
NOTCH3 C93*	3	None Identified
TP53 P278T	2C	5 Clinical Trials

Tumor Mutation Burden: 9.2 mut/Mb (Low) | **MSI Status:** MSS (Microsatellite Stable)

Pertinent NEGATIVE Results

BRAF V600E, NTRK1/2/3 fusion, RET fusion | HER2 (ERBB2) gain, POLD1 mut | NRAS mut (exons 2,3,4), POLE mut

Potential Hereditary Findings *Based on ACMG secondary findings genes. Consider genetic counseling, if appropriate*

APC E1494fs (Familial adenomatous polyposis)
TP53 P278T (Li-Fraumeni syndrome)

Testing Summary

All test components were successfully performed.

Signed by: John Doe

ACTIONABILITY SUMMARY

FDA / NCCN Therapies for the Patient's Tumor Type (Tier 1A)

Biomarker	Therapies	Setting	Source(s)
KRAS G12C	adagrasib + cetuximab	Subsequent line	FDA (Approved), NCCN
KRAS G12C	adagrasib +/- panitumumab; sotorasib +/- (cetuximab or panitumumab)	Subsequent line	NCCN

Chronetyx Laboratories, 3171 Players Club Pkwy, Memphis, TN 38125
CLIA# 44D2293926 | Abdallah Azouz, MD, Laboratory Director
ETCR-KEU-201:BM80908_2_R1:240920090005 | Signed by John Doe, M.D. | 2024-09-25

p.1/7

Ready to Get Started?
Call, email, or scan for more info

800-454-2137
info@chronetyx.com